National Beverage Dips Despite Link with WNBA
LaCroix Sparkling Water by National Beverage Corp. (NASDAQ: FIZZ) today announced a new partnership with the Dallas Wings Women's National Basketball Association (WNBA) team.The partnership includes prominent placement of the LaCroix logo on the official Wings warm-up jackets and shooting shirts, along with rotational signage and game-night activation samplings. LaCroix will also be featured as part of the Dallas Wings Youth Basketball Program.“This alliance with the Wings is part of our continuing mission to enhance consumer brand recognition and loyalty through a combination of participation in events, sponsorships and endorsements. Dallas is the fourth largest, and one of the fastest-growing, metropolitan areas in the U.S., and LaCroix is elated to collaborate with the Dallas Wings and engage with its fans. In addition to the Wings, we currently sponsor various women’s professional soccer and basketball teams along with men’s professional soccer and hockey teams,” stated a LaCroix spokesperson.“The Dallas Wings is an exciting team featuring the talent of rookie Paige Bueckers. Bueckers, who was just chosen as an All-Star starter in her rookie year, is breaking records and exhilarating fans. LaCroix is the perfect partner for this young and vibrant team that is dedicated to supporting local community and youth,” the spokesperson concluded.FIZZ shares fell 69 cents, or 1.5%, to $44.29.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


